Omvoh™ (mirikizumab-mrkz) - Prior Authorization/Notification - UnitedHealthcare Commercial Plansopen_in_new
Prior authorization/notification requirements for the subcutaneous formulation of Omvoh (mirikizumab-mrkz) for treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults for UnitedHealthcare Commercial Plans; includes initial authorization, reauthorization, and additional clinical rules.
Added coverage criteria for Crohn's disease.
Annual review with no change to clinical criteria; updated examples and reference.
Updated background and reference to package insert (January 2025).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.